SBT-272

SBT-272, also designated bevemipretide (International Nonproprietary Name), is a clinical-stage mitochondria-targeted peptidomimetic small molecule developed by Stealth BioTherapeutics as a structurally optimized successor to elamipretide (SS-31, MTP-131, Bendavia). The compound selectively binds cardiolipin, a diphosphatidylglycerol lipid exclusively localized to the inner mitochondrial membrane, where it stabilizes the organization of electron transport chain complexes into supercomplexes (respirasomes), promotes efficient oxidative phosphorylation, reduces mitochondrial reactive oxygen species generation, and prevents the cytochrome c/cardiolipin peroxidase activity that initiates apoptotic signaling. Relative to the first-generation elamipretide scaffold, SBT-272 demonstrates higher mitochondrial uptake, greater brain accumulation following subcutaneous administration, and improved systemic bioavailability in preclinical species, properties that position the compound for neurodegenerative disease indications where central nervous system exposure is a critical determinant of therapeutic effect.

The preclinical pharmacology of SBT-272 encompasses multiple neurodegenerative disease models. In TDP-43 mutant upper motor neuron cultures derived from the prpTDP-43(A315T) transgenic mouse, SBT-272 restored mitochondrial structural integrity, recovered mitochondrial motility in a dose-dependent manner, and improved axon outgrowth, a functional indicator of neuronal health, with effects superior to those of edaravone and AMX0035 in the same system [1]. Chronic in vivo treatment for sixty days in the same model significantly reduced astrogliosis, microgliosis, and TDP-43 pathology in the motor cortex [1]. In the SOD1(G93A) transgenic mouse model of amyotrophic lateral sclerosis, high-dose SBT-272 (5.0 mg/kg/day intraperitoneal) delayed neurological symptom onset and significantly extended lifespan in male mice [2]. In an alpha-synucleinopathy mouse model of Parkinson's disease, daily subcutaneous SBT-272 attenuated dopaminergic neuron loss, reduced pathological alpha-synuclein burden, and suppressed neuroinflammatory markers [3]. Additional preclinical neuroprotective activity has been reported in models of frontotemporal lobar dementia, Huntington's disease, and ischemic stroke [4].

Clinical development has advanced through a Phase 1 double-blind, placebo-controlled study in healthy volunteers evaluating subcutaneous SBT-272 at single ascending doses of 5 to 60 mg and multiple ascending doses of 20, 40, and 60 mg daily for 7 days [5]. Interim results demonstrated a pharmacokinetic profile consistent with preclinical allometric scaling predictions, plasma and projected brain exposures at doses anticipated to reach therapeutic concentrations based on preclinical efficacy thresholds, and a safety profile in which the most commonly reported adverse event was mild-to-moderate injection site reaction resolving within approximately 4 hours of dosing [5]. The United States Food and Drug Administration granted Orphan Drug Designation for SBT-272 for the treatment of amyotrophic lateral sclerosis in 2022 [4]. A separate development program for topical ocular bevemipretide (eye drops) in dry age-related macular degeneration has advanced through preclinical studies demonstrating approximately 4- to 6-fold higher retinal tissue concentrations compared to elamipretide, with a 13-week GLP toxicology study informing Phase 1 trial design [6, 7].

This monograph reviews the chemistry, structural class, and synthesis of SBT-272; the cardiolipin-stabilization mechanism at the inner mitochondrial membrane; the pharmacokinetic profile including brain penetration; the preclinical pharmacology across ALS, Parkinson's disease, and additional neurodegenerative models; the Phase 1 clinical evidence base; sourcing and quality verification considerations; reconstitution and handling; stack-interaction implications; adverse-event signal; and a comparative assessment of five mitochondria-targeted or neuroprotective candidates against SBT-272 on five competency standards (novelty, effect size, promising potential, side-effect profile, and overall validation).